HRD Test and PARP Inhibitors in Ovarian Cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies how a gene test called HRD (which looks for DNA repair problems in your tumor) relates to how well a type of drug called a PARP inhibitor works for ovarian cancer. It aims to help doctors choose the best treatment for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian cancer (any type).
- You need to be 18 years old or older.
- You should not have any other active cancers.
- You must have a CT or MRI scan before starting treatment.
- You need to have at least one tumor that can be measured on a scan.
- You must agree to share your tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a genetic test called HRD to see if it can predict how well PARP inhibitors (a type of targeted therapy) work for ovarian cancer patients. It is for women who have been treated with platinum chemotherapy and are now on PARP inhibitor maintenance therapy.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.